NEONC TECHNOLOGIES HOLDINGS, INC.
NTHI$68M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCALABASAS
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Dec 30, 2026
35wMarket Overview
Stock performance and key metrics
NTHI News
Catalyst Timeline
2 upcoming, 2 past
Drug Pipeline
NEO212 Oral Capsule
Diffuse Astrocytoma, IDH-Mutant
Perillyl alcohol
Glioblastoma Multiforme
NEO100
Residual, Progressive or Recurrent Grade II or III Meningioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NEO212 Oral Capsule | Phase 2 | Diffuse Astrocytoma, IDH-Mutant | - | - |
Perillyl alcohol | Phase 2 | Glioblastoma Multiforme | - | - |
NEO100 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply